This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sakowicz, R. Articles by Wood, K. W. Search for Related Content PubMed PubMed Citation Articles by Sakowicz, R. Articles by Wood, K. W.

Antitumor Activity of a Kinesin Inhibitor

¹ Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas; and ² Cytokinetics, Inc., South San Francisco, California

Several members of the kinesin family of microtubule motor proteins play essential roles in mitotic spindle function and are potential targets for the discovery of novel antimitotic cancer therapies. KSP, also known as HsEg5, is a kinesin that plays an essential role in formation of a bipolar mitotic spindle and is required for cell cycle progression through mitosis. We identified a potent inhibitor of KSP, CK0106023, which causes mitotic arrest and growth inhibition in several human tumor cell lines. Here we show that CK0106023 is an allosteric inhibitor of KSP motor domain ATPase with a K_i of 12 nM. Among five kinesins tested, CK0106023 was specific for KSP. In tumor-bearing mice, CK0106023 exhibited antitumor activity comparable to or exceeding that of paclitaxel and caused the formation of monopolar mitotic figures identical to those produced in cultured cells. KSP was most abundant in proliferating human tissues and was absent from cultured postmitotic neurons. These findings are the first to demonstrate the feasibility of targeting mitotic kinesins for the treatment of cancer.

This article has been cited by other articles:

				R. Nakai, S.-i. Iida, T. Takahashi, T. Tsujita, S. Okamoto, C. Takada, K. Akasaka, S. Ichikawa, H. Ishida, H. Kusaka, et al. K858, a Novel Inhibitor of Mitotic Kinesin Eg5 and Antitumor Agent, Induces Cell Death in Cancer Cells Cancer Res., May 1, 2009; 69(9): 3901 - 3909. [Abstract] [Full Text] [PDF]

				M. Liu, R. Aneja, X. Sun, S. Xie, H. Wang, X. Wu, J.-T. Dong, M. Li, H. C. Joshi, and J. Zhou Parkin Regulates Eg5 Expression by Hsp70 Ubiquitination-dependent Inactivation of c-Jun NH2-terminal Kinase J. Biol. Chem., December 19, 2008; 283(51): 35783 - 35788. [Abstract] [Full Text] [PDF]

				V. Sarli and A. Giannis Targeting the Kinesin Spindle Protein: Basic Principles and Clinical Implications Clin. Cancer Res., December 1, 2008; 14(23): 7583 - 7587. [Abstract] [Full Text] [PDF]

				G. Wu, X.-L. Qiu, L. Zhou, J. Zhu, R. Chamberlin, J. Lau, P.-L. Chen, and W.-H. Lee Small Molecule Targeting the Hec1/Nek2 Mitotic Pathway Suppresses Tumor Cell Growth in Culture and in Animal Cancer Res., October 15, 2008; 68(20): 8393 - 8399. [Abstract] [Full Text] [PDF]

				T. C. Krzysiak, M. Grabe, and S. P. Gilbert Getting in Sync with Dimeric Eg5: INITIATION AND REGULATION OF THE PROCESSIVE RUN J. Biol. Chem., January 25, 2008; 283(4): 2078 - 2087. [Abstract] [Full Text] [PDF]

				Y. Furukawa, T. Shimada, H. Furuta, S. Matsuno, A. Kusuyama, A. Doi, M. Nishi, H. Sasaki, T. Sanke, and K. Nanjo Polymorphisms in the IDE-KIF11-HHEX Gene Locus Are Reproducibly Associated with Type 2 Diabetes in a Japanese Population J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 310 - 314. [Abstract] [Full Text] [PDF]

				K. M.R. Bhat and V. Setaluri Microtubule-Associated Proteins as Targets in Cancer Chemotherapy Clin. Cancer Res., May 15, 2007; 13(10): 2849 - 2854. [Abstract] [Full Text] [PDF]

				D. Tripathy Capecitabine in Combination with Novel Targeted Agents in the Management of Metastatic Breast Cancer: Underlying Rationale and Results of Clinical Trials Oncologist, April 1, 2007; 12(4): 375 - 389. [Abstract] [Full Text] [PDF]

				U. Vijapurkar, W. Wang, and R. Herbst Potentiation of Kinesin Spindle Protein Inhibitor-Induced Cell Death by Modulation of Mitochondrial and Death Receptor Apoptotic Pathways Cancer Res., January 1, 2007; 67(1): 237 - 245. [Abstract] [Full Text] [PDF]

				T. C. Krzysiak and S. P. Gilbert Dimeric Eg5 Maintains Processivity through Alternating-site Catalysis with Rate-limiting ATP Hydrolysis J. Biol. Chem., December 22, 2006; 281(51): 39444 - 39454. [Abstract] [Full Text] [PDF]

				G. M. Chin and R. Herbst Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint. Mol. Cancer Ther., October 1, 2006; 5(10): 2580 - 2591. [Abstract] [Full Text] [PDF]

				R. H. Wilson Novel Therapeutic Developments Other Than EGFR and VEGF Inhibition in Colorectal Cancer Oncologist, October 1, 2006; 11(9): 1018 - 1024. [Abstract] [Full Text] [PDF]

				D. A. Skoufias, S. DeBonis, Y. Saoudi, L. Lebeau, I. Crevel, R. Cross, R. H. Wade, D. Hackney, and F. Kozielski S-Trityl-L-cysteine Is a Reversible, Tight Binding Inhibitor of the Human Kinesin Eg5 That Specifically Blocks Mitotic Progression J. Biol. Chem., June 30, 2006; 281(26): 17559 - 17569. [Abstract] [Full Text] [PDF]

				M. Liu, R. Aneja, C. Liu, L. Sun, J. Gao, H. Wang, J.-T. Dong, V. Sarli, A. Giannis, H. C. Joshi, et al. Inhibition of the Mitotic Kinesin Eg5 Up-regulates Hsp70 through the Phosphatidylinositol 3-Kinase/Akt Pathway in Multiple Myeloma Cells J. Biol. Chem., June 30, 2006; 281(26): 18090 - 18097. [Abstract] [Full Text] [PDF]

				M. S. Ricci and W.-X. Zong Chemotherapeutic approaches for targeting cell death pathways. Oncologist, April 1, 2006; 11(4): 342 - 357. [Abstract] [Full Text] [PDF]

				Z. Maliga, J. Xing, H. Cheung, L. J. Juszczak, J. M. Friedman, and S. S. Rosenfeld A Pathway of Structural Changes Produced by Monastrol Binding to Eg5 J. Biol. Chem., March 24, 2006; 281(12): 7977 - 7982. [Abstract] [Full Text] [PDF]

				K. J. Pienta and D. Bradley Mechanisms underlying the development of androgen-independent prostate cancer. Clin. Cancer Res., March 15, 2006; 12(6): 1665 - 1671. [Full Text] [PDF]

				E. Koller, S. Propp, H. Zhang, C. Zhao, X. Xiao, M. Chang, S. A. Hirsch, P. J. Shepard, S. Koo, C. Murphy, et al. Use of a Chemically Modified Antisense Oligonucleotide Library to Identify and Validate Eg5 (Kinesin-Like 1) as a Target for Antineoplastic Drug Development Cancer Res., February 15, 2006; 66(4): 2059 - 2066. [Abstract] [Full Text] [PDF]

				G. K. Schwartz and M. A. Shah Targeting the Cell Cycle: A New Approach to Cancer Therapy J. Clin. Oncol., December 20, 2005; 23(36): 9408 - 9421. [Abstract] [Full Text] [PDF]

				R. D. Loberg, C. J. Logothetis, E. T. Keller, and K. J. Pienta Pathogenesis and Treatment of Prostate Cancer Bone Metastases: Targeting the Lethal Phenotype J. Clin. Oncol., November 10, 2005; 23(32): 8232 - 8241. [Abstract] [Full Text] [PDF]

				A. Wallqvist, R. Huang, D. G. Covell, A. V. Roschke, K. S. Gelhaus, and I. R. Kirsch Drugs aimed at targeting characteristic karyotypic phenotypes of cancer cells Mol. Cancer Ther., October 1, 2005; 4(10): 1559 - 1568. [Abstract] [Full Text] [PDF]

				G. Goshima and R. D. Vale Cell Cycle-dependent Dynamics and Regulation of Mitotic Kinesins in Drosophila S2 Cells Mol. Biol. Cell, August 1, 2005; 16(8): 3896 - 3907. [Abstract] [Full Text] [PDF]

				C. Zhu, J. Zhao, M. Bibikova, J. D. Leverson, E. Bossy-Wetzel, J.-B. Fan, R. T. Abraham, and W. Jiang Functional Analysis of Human Microtubule-based Motor Proteins, the Kinesins and Dyneins, in Mitosis/Cytokinesis Using RNA Interference Mol. Biol. Cell, July 1, 2005; 16(7): 3187 - 3199. [Abstract] [Full Text] [PDF]

				R. Claus, U. Lenschow, T. Kulz, A. Kotitschke, D. Meiske, H.-J. Thiesen, and P. Lorenz Congenital heart block associated with a maternal anti-HsEg5-like autoantibody Rheumatology, May 1, 2005; 44(5): 691 - 693. [Full Text] [PDF]

				J. C. Cochran, J. E. Gatial III, T. M. Kapoor, and S. P. Gilbert Monastrol Inhibition of the Mitotic Kinesin Eg5 J. Biol. Chem., April 1, 2005; 280(13): 12658 - 12667. [Abstract] [Full Text] [PDF]

				L. D. Belmont Mitotic Kinesins as Targets for Anticancer Therapy Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 173 - 177. [Full Text] [PDF]

				A. I. Marcus, U. Peters, S. L. Thomas, S. Garrett, A. Zelnak, T. M. Kapoor, and P. Giannakakou Mitotic Kinesin Inhibitors Induce Mitotic Arrest and Cell Death in Taxol-resistant and -sensitive Cancer Cells J. Biol. Chem., March 25, 2005; 280(12): 11569 - 11577. [Abstract] [Full Text] [PDF]

				C. Kung, D. M. Kenski, S. H. Dickerson, R. W. Howson, L. F. Kuyper, H. D. Madhani, and K. M. Shokat Chemical genomic profiling to identify intracellular targets of a multiplex kinase inhibitor PNAS, March 8, 2005; 102(10): 3587 - 3592. [Abstract] [Full Text] [PDF]

				D. Carvajal, C. Tovar, H. Yang, B. T. Vu, D. C. Heimbrook, and L. T. Vassilev Activation of p53 by MDM2 Antagonists Can Protect Proliferating Cells from Mitotic Inhibitors Cancer Res., March 1, 2005; 65(5): 1918 - 1924. [Abstract] [Full Text] [PDF]

				S. DeBonis, D. A. Skoufias, L. Lebeau, R. Lopez, G. Robin, R. L. Margolis, R. H. Wade, and F. Kozielski In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities Mol. Cancer Ther., September 1, 2004; 3(9): 1079 - 1090. [Abstract] [Full Text] [PDF]